Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 8/20 | 0.66 |
| ▸ | RAB9A | P51151 | 8/20 | 0.66 |
| ▸ | GAA | P10253 | 6/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.66 |
| ▸ | HPGD | P15428 | 3/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | HTT | P42858 | 2/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | GFER | P55789 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | SHMT2 | P34897 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8738054 | 0.85 | NPC1 (0.54) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL17924299 | 0.84 | NPC1 (0.55) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL10145473 | 0.84 | NPC1 (0.52) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL541672 | 0.84 | NPC1 (0.52) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL29880555 | 0.84 | NPC1 (0.52) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL12953976 | 0.84 | NPC1 (0.52) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL4592448 | 0.83 | NPC1 (0.85) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL21240926 | 0.83 | NPC1 (0.52) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL23478960 | 0.81 | NPC1 (0.50) | NPC1RAB9AGAAKDM4ESMN1; SMN2 | |
| SCHEMBL6125744 | 0.81 | NPC1 (0.50) | NPC1RAB9AGAAKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12030853-B2 | MASP-2 inhibitors and methods of use | OMEROS CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| WO-2023154124-A1 | ACYLATED HETEROCYCLIC QUINAZOLINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | VANDERBILT UNIVERSITY | 2023-06-15 | — | — | US | disclosed |
| WO-2023092175-A1 | NOVEL P2X7 RECEPTOR ANTAGONISTS | THE UNIVERSITY OF SYDNEY (AU) | 2023-06-01 | — | — | WO | disclosed |
| WO-2022140769-A1 | LACTAM (HETERO)ARYLFUSEDPYRIMIDINE DERIVATIVES AS INHIBITORS OF ERBB2 | ENLIVEN THERAPEUTICS, INC. (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2021114315-A1 | USE OF HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES | SHANGHAI EAST HOSPITAL (CN) | 2021-06-17 | — | — | WO | disclosed |
| WO-2021114314-A1 | NOVEL HETEROCYCLIC DERIVATIVES WITH CARDIOMYOCYTE PROLIFERATION ACTIVITY FOR TREATMENT OF HEART DISEASES | TONGJI UNIVERSITY (CN) | 2021-06-17 | — | — | WO | disclosed |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | OMEROS CORPORATION | 2021-06-10 | — | — | US | disclosed |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-12-15 | — | — | US | disclosed |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2020-12-15 | — | — | US | disclosed |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | AMGEN INC (US) | 2015-01-29 | — | — | US | disclosed |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | AMGEN INC. (US) | 2014-06-19 | — | — | US | disclosed |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | TREVENA, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TRIUS THERAPEUTICS, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2012-02-16 | — | — | US | disclosed |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ARRAY BIOPHARMA, INC. | 2011-02-10 | — | — | US | disclosed |
| US-20100267689-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N. V. (BE) | 2010-10-21 | — | — | US | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | CORBETT JEFFREY WAYNE | 2009-10-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | NPC1 4024/4885RAB9A 2919/4885GAA 2777/4885 |
| US-20150031668-A1 | CHROMAN DERIVATIVES AS TRPM8 INHIBITORS | TRPM8, TRPM5, TRPM7 | NPC1 702/4885RAB9A 1056/4885GAA 780/4885 |
| US-20120238751-A1 | TRICYCLIC GYRASE INHIBITORS | TOP1, TOP2A, TOP2B | NPC1 1885/4885RAB9A 3316/4885GAA 85/4885 |
| US-20110034689-A1 | N4-Phenyl-Quinazoline-4-Amine Derivatives and Related Compounds as ErbB Type I Receptor Tyrosine Kinase Inhibitors for the Treatment of Hyperproliferative Diseases | ERBB4, ERBB2, ERBB3 | NPC1 2037/4885RAB9A 1344/4885GAA 2375/4885 |
| US-20230183237-A1 | COMPETITIVE AND NONCOMPETITIVE INHIBITORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M5 | CHRM5, CHRM1, CHRM2 | NPC1 2563/4885RAB9A 1907/4885GAA 4089/4885 |
| US-20120040960-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | NPC1 1303/4885RAB9A 4177/4885GAA 3203/4885 |
| US-10864202-B2 | Inhibitors of lysine specific demethylase-1 | KDM1B, KDM1A, KDM3A | NPC1 4332/4885RAB9A 3036/4885GAA 1295/4885 |
| US-20090270435-A1 | Spiroketone Acetyl-CoA Carboxylase Inhibitors | ACACA, PC, ACACB | NPC1 715/4885RAB9A 1738/4885GAA 1471/4885 |
| US-20140171406-A1 | TRPM8 ANTAGONISTS AND THEIR USE IN TREATMENTS | TRPM8, TRPM7, TRPM5 | NPC1 533/4885RAB9A 1520/4885GAA 1524/4885 |
| US-10865216-B2 | Tricyclic Gyrase inhibitors | TOP1, TOP2A, TOP2B | NPC1 1992/4885RAB9A 3133/4885GAA 82/4885 |
| US-12030853-B2 | MASP-2 inhibitors and methods of use | MASP2, METAP2, SPINT2 | NPC1 2354/4885RAB9A 2027/4885GAA 1678/4885 |
| US-20120245181-A1 | OPIOID RECEPTOR LIGANDS AND METHODS OF USING AND MAKING SAME | OPRL1, OPRK1, OPRM1 | NPC1 3008/4885RAB9A 3140/4885GAA 3375/4885 |
| US-20210171461-A1 | MASP-2 INHIBITORS AND METHODS OF USE | MASP2, METAP2, SPINT2 | NPC1 2354/4885RAB9A 2027/4885GAA 1678/4885 |
| US-20100267689-A1 | 4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | NPC1 1303/4885RAB9A 4177/4885GAA 3203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.